Currently PTCL is treated similarly to B-cell<unk> s. However, in recent years, scientists have developed techniques to better recognize the different types of<unk> s, such as PTCL. It is now understood that PTCL behaves differently from B-cell<unk> s and therapies are being developed that specifically target these types of<unk> . Currently, however, there are no therapies approved by the US Food and Drug Administration (FDA) specifically for PTCL. Anthracycline-containing chemotherapy regimens are commonly offered as the initial therapy. Some patients may receive a stem cell transplant. Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation. Pralatrexate and cerdulatinib are some of the compounds currently under investigations for the treatment of PTC.
Peripheral T-cell lymphoma not otherwise specified
Pediatric-type follicular lymphoma
Nodal marginal zone B cell lymphoma
Angioimmunoblastic T-cell lymphoma
Blastic plasmacytoid dendritic cell neoplasm
Diffuse infiltrative lymphocytosis syndrome
Hemophagocytic lymphohistiocytosis
Pleomorphic T-cell lymphoma